March 18, 2024

SciSparc Doses First Patient in Autism Treatment Trial

SciSparc Ltd. (Nasdaq: SPRC) has successfully dosed the first patient in its SCI-210 clinical trial for pediatric patients with Autism Spectrum Disorder (ASD). This is a significant milestone for the company as it evaluates its proprietary SCI-210 treatment, a combination of cannabidiol-rich oil (CBD) and CannAmide™ palmitoylethanolamide-based tablets in its quest to offer a safer… [Read More]
March 18, 2024

Fennec Pharmaceuticals to Commercialize Protective Treatment for Chemotherapy-Induced Hearing Loss

Shares in commercial stage pharmaceutical company, Fennec Pharmaceuticals Inc. (Nasdaq: FENC), rose 11% in morning trading on Monday after the company announced it will partner with Norgine, a leading European specialist pharmaceutical company, to commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the EU and UK… [Read More]
March 18, 2024

Is the Options Market Predicting a gain in Canoo (GOEV) Stock?

Shareholders of Canoo Inc., GOEV, should keep a close eye on the behavior of the stock given recent activity in the options market. Notably, the Apr 19, 2024 $1.50 Call demonstrated some of the most significant implied volatility of all equity options today. Understanding Implied Volatility Implied volatility is a measurement of how much sway… [Read More]
March 18, 2024

Alphabet’s stock up 7% on report Apple is in talks to license Gemini AI for iPhones

Alphabet’s stock surged by over 7% on Monday upon the release of a report suggesting that Apple is in discussions about incorporating Google’s AI toolset, Gemini, into forthcoming iPhones. Apple’s stocks also witnessed a more than 2% increase. Gemini, a product of Google, consists of an array of generative artificial intelligence resources ranging from chatbots… [Read More]
March 18, 2024

Stocks making the biggest moves premarket: Google, HashiCorp, Nvidia and more

Alphabet’s Class A shares, which belong to Google’s parent company, saw an upturn of 5.6% due to talk of a partnership with Apple. A Bloomberg report suggests Apple may incorporate Google’s Gemini AI engine into their future iPhone systems. Super Micro Computer’s shares climbed by 2.5%. This technology company, specializing in artificial intelligence servers, is… [Read More]
March 16, 2024

New and Improved: Rebranding Liver Disease to Change Outcomes for Patients

This week, Madrigal Therapeutics (Nasdaq: MDGL) won FDA approval for Rezdiffra™, the first and only drug to be approved for metabolic dysfunction-associated steatohepatitis (MASH). The landmark decision has shone a light on MASH, an advanced liver disease, and a leading cause of liver-related mortality, that affects between six and eight million adults in the US…. [Read More]
March 15, 2024

NeuroBo Secures Safety Review Committee Approval for MASH Treatment Trial

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has received Safety Review Committee (SRC) approvalrecommending that the company’s two-part Phase 2a trial of DA-1241, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), continue without modification following a blinded safety review of the first six months of study conduct. Commenting on the news, Hyung Heon Kim, President and Chief… [Read More]
March 15, 2024

New Frontiers: Lantern Pharma Doses First Patient in AI-Guided Clinical Trial

Artificial intelligence company, Lantern Pharma Inc. (Nasdaq: LTRN), is advancing a pipeline of AI-driven therapies to patients. On Friday, the company announced it has dosed the first two patients in a Phase 1 clinical trial evaluating LP-284 in patients with hematologic cancers as well as other select solid tumors and sarcomas. Lantern’s share price rose… [Read More]
March 15, 2024

FDA Accelerated Approval for Madrigal’s Rezdiffra™ in Win for NASH Patients

Shares in Madrigal Pharmaceuticals (Nasdaq: MDGL) soared this week after the FDA granted accelerated approval of the company’s drug candidate Rezdiffra™ in the treatment of nonalcoholic steatohepatitis (NASH). This represents the first and only drug to be approved for NASH, an advanced liver disease and a leading cause of liver-related mortality, that affects between 1.5%… [Read More]